In view of these changes in recommendations, namely the recent addition of PALB2, but not CHEK2, to UK genetic testing guidance, we report our single-center experience to date of germline PALB2 and CHEK2 c.1100delC; p.(Thr367MetfsTer15) (CHEK2_1100delC) testing in breast/ovarian cancer; these data will help provide evidence for future testing guidance. Here, CHEK2 is linked to ovarian carcinoma.